12.38
-0.03 (-0.28%)
| Penutupan Terdahulu | 12.42 |
| Jumlah Dagangan | 56,640 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.47 |
| Harga / Jualan (P/S) | 3.94 |
| Harga / Buku (P/B) | 1.71 |
| Julat 52 Minggu |
| Margin Keuntungan | 5.99% |
| Margin Operasi (TTM) | -4.99% |
| EPS Cair (TTM) | 0.200 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.40% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -84.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.64% |
| Nisbah Semasa (MRQ) | 2.83 |
| Aliran Tunai Operasi (OCF TTM) | -46.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -50.75 M |
| Pulangan Atas Aset (ROA TTM) | -2.14% |
| Pulangan Atas Ekuiti (ROE TTM) | 5.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | HUTCHMED (China) Limited | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | 0.5 |
| Purata | -1.57 |
|
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.12% |
| % Dimiliki oleh Institusi | 3.87% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Aia Group Ltd | 30 Jun 2026 | 291,229 |
| Xy Capital Ltd | 30 Jun 2026 | 104,130 |
| Crossmark Global Holdings, Inc. | 30 Jun 2026 | 84,915 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |